Agamree access in UAE: the EDE named-patient pathway
How UAE patients legally obtain Agamree (vamorolone) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Ask about Agamree in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Agamree (vamorolone) is a dissociative steroid (a corticosteroid with reduced bone, growth, and metabolic side effects) approved by the US FDA in October 2023 for Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. The drug is manufactured by Catalyst Pharmaceuticals (Santhera US partner). UAE patients use the Emirates Drug Establishment named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written. Reserve Meds coordinates supply through a US-licensed pharmaceutical wholesale partner, builds the documentation packet your physician needs to file, and orchestrates the logistics into UAE with a single point of contact carrying the case end-to-end.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Agamree reaches patients in the UAE
Agamree (vamorolone, a dissociative steroid for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older, FDA-approved October 2023; marketed by Catalyst Pharmaceuticals after Santhera Pharmaceuticals' Americas licensing deal) is not currently registered with MOHAP or EDE and is not visible on the MOHAP services portal at mohap.gov.ae/en/services as of 2026-05-31. UAE residents access Agamree through the Permit to Import Medicines for Personal Use, administered by the Emirates Drug Establishment (EDE) since 29 December 2025 (the service was transferred from MOHAP to EDE per mohap.gov.ae/en/mte). Applications file through the EDE online portal at ede.gov.ae; the EDE infographic on personal-use import is at ede.gov.ae EDE personal-use import infographic. The legal basis is Federal Law No. 8 of 2019 on Medical Products. The Agamree-specific clinical justification must document: confirmed DMD diagnosis by genetic testing (deletion/duplication or sequencing of DMD gene), age 2 years or older, baseline ambulatory status, baseline weight and growth chart for paediatric patient, and the prescribing paediatric neurologist's UAE-licensed status with the relevant Health Authority (DoH Abu Dhabi or DHA). EDE permits are issued for a 3-month supply per cycle.
Where Agamree is dispensed in the UAE
Agamree is a paediatric chronic oral therapy administered in paediatric-neurology outpatient settings with growth, bone-mineral-density, and behavioural-monitoring schedules. Al Jalila Children's Specialty Hospital and CCAD publish departmental rosters and run structured DMD clinics. The corticosteroid-class comparison (prednisone, prednisolone, deflazacort) is the historical standard; vamorolone offers a different bone-mineral and growth-velocity profile relevant to paediatric DMD families.
What Agamree costs in the UAE
Medicine price: quote on request. You get a written quote for your case before you commit. Do not estimate. For Emirati national paediatric DMD patients on Thiqa-administered Daman insurance at SEHA facilities, the funding path is typically through institutional channels with prior authorisation rather than personal-import OOP.
Funding and access barriers for Agamree in the UAE
DMD is a rare X-linked recessive paediatric neuromuscular disease with incidence approximately 1 in 3,500 male live births. The UAE DMD cohort is well-recognised at Al Jalila Children's Specialty Hospital and CCAD with structured clinical-genetics support. Public-sector funding: for Emirati nationals, Thiqa-administered Daman insurance at daman.ae in Abu Dhabi covers specialty paediatric care including DMD management at SEHA facilities; named-patient imports require prior authorisation. Dubai-resident Emirati nationals on Salama or ENAYA receive comparable specialty care via DHA-supervised channels. MOHAP-administered free care for Emirati nationals applies in the Northern Emirates. The Patient Affairs Department in the Office of HH Sheikh Mohamed bin Zayed (Abu Dhabi) and the Mohammed bin Rashid Foundation (Dubai) operate case-by-case grants for high-cost paediatric specialty treatment. Major UAE private insurers (Daman National Health Insurance, Bupa Arabia, AXA Gulf, MetLife, Sukoon, Cigna Middle East, Allianz Worldwide Care, Mednet, Nextcare TPA, NAS TPA) under mandatory health insurance in Dubai and Abu Dhabi cover a minimum essential benefits package; Agamree as a recently FDA-approved DMD-specific therapy requires prior authorisation and is coverage-tier dependent. The Catalyst Pharmaceuticals patient-support programme operates case-by-case for ex-US markets. The EDE permit for the oral suspension is procedurally straightforward; cold-chain logistics is the main operational step.
Recent regulatory and access news for Agamree
FDA approved Agamree on 26 October 2023 for DMD in patients 2 years and older based on the VISION-DMD phase 2b trial; the FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA (CHMP) issued a positive opinion for vamorolone in 2023 with subsequent European Commission marketing authorisation; the EPAR is at ema.europa.eu/medicines/Agamree. MOHAP announced on 29 December 2025 the transfer of personal-use import permit service (and selected other services) to the Emirates Drug Establishment (EDE) per mohap.gov.ae/en/mte; all UAE personal-import applications including for Agamree now route through ede.gov.ae as of 2026-05-31. MOHAP and EDE periodic guideline updates on import of medicines from local agents continue at mohap.gov.ae.
Where Reserve Meds fits in Agamree cases
Reserve Meds is a US-based digital health company. We do not replace your UAE specialist, we do not replace the EDE, and we do not replace your dispensing pharmacy. For Agamree specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate logistics into UAE, and give you one point of contact through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.
Next step
If your UAE physician has prescribed Agamree and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.